DHA inhibits invasion and metastasis in NSCLC cells by interfering with CCL18/STAT3 signaling pathway

Hai-Qing Luo1, Yu-Meng Huang2, Jing Li3,4

  • 1Center of Oncology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, People's Republic of China. hqluo@126.com.

Insights

Omega-3 fatty acids, specifically DHA, inhibit non-small cell lung cancer (NSCLC) metastasis by downregulating CCL18 expression and the STAT3 pathway. This finding offers a potential therapeutic strategy for lung cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Omega-3 fatty acids show antitumor potential, but mechanisms in lung cancer metastasis are unclear.
  • Chemokine ligand 18 (CCL18) expression correlates with non-small cell lung cancer (NSCLC) migration and metastasis.
  • Investigating omega-3's role in regulating CCL18 is crucial for understanding lung cancer progression.

Purpose of the Study:

  • To determine if omega-3 fatty acids inhibit NSCLC invasion and metastasis by regulating CCL18 expression.
  • To elucidate the molecular mechanisms underlying omega-3's anti-metastatic effects in NSCLC.
  • To explore the relationship between CCL18, STAT3 signaling, and epithelial-mesenchymal transition (EMT) in NSCLC.

Main Methods:

  • Quantitative real-time PCR (RT-qPCR) and Western blotting to assess gene and protein expression.
  • Scratch wound healing and Transwell assays to evaluate cell migration and invasion.
  • Investigated the effects of docosahexaenoic acid (DHA) and CCL18 overexpression on NSCLC cell behavior and signaling pathways.

Main Results:

  • CCL18 levels positively correlate with NSCLC metastatic potential.
  • DHA significantly inhibited NSCLC cell invasion and metastasis.
  • DHA downregulated metastasis-related genes, EMT markers, and the p-STAT3 signaling pathway.
  • CCL18 overexpression reversed DHA's inhibitory effects, restoring metastatic gene expression and cell invasion.

Conclusions:

  • Docosahexaenoic acid (DHA), an omega-3 fatty acid, inhibits NSCLC invasion and metastasis.
  • DHA likely exerts its effects by downregulating CCL18 expression and inhibiting the STAT3 signaling pathway and EMT.
  • Targeting the CCL18/STAT3 pathway presents a potential therapeutic strategy for managing NSCLC metastasis.